secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000010795-24-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q2 revenue $5.0B (+4.6%), adj. EPS $3.17 (+10.8%); raises FY24 adjusted EPS guidance
--------------------------------------------------------------------------------

- Q2 revenue $5,045M (+4.6% reported, +5.7% organic); GAAP diluted EPS $1.85 (+20.9%), adjusted EPS $3.17 (+10.8%).
- Year-to-date Cash from Ops $1.4B; Free Cash Flow $1.1B, up >$900M YoY.
- Company raises full-year adjusted EPS guidance and affirms organic revenue growth forecast.
- BD Medical increasing domestic syringe production after FDA safety communication on non-BD syringes.
- BD Life Sciences launched three- and four-laser additions to BD FACSDiscover S8 Cell Sorter family.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000036/0000010795-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079524000036/bdx-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000010795-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer